BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $78.85 Average Target Price from Analysts

BridgeBio Pharma, Inc. (NASDAQ:BBIO) has received a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and twenty-two have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $78.85.

Several research firms recently weighed in on BBIO. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, October 8th. Morgan Stanley assumed coverage on shares of BridgeBio Pharma in a research note on Tuesday, January 6th. They issued an “overweight” rating and a $96.00 price target for the company. TD Cowen lifted their price objective on shares of BridgeBio Pharma from $60.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Piper Sandler boosted their price objective on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $71.00 target price (up from $69.00) on shares of BridgeBio Pharma in a report on Thursday, October 30th.

BridgeBio Pharma Stock Performance

NASDAQ:BBIO opened at $76.26 on Friday. BridgeBio Pharma has a 52-week low of $28.33 and a 52-week high of $79.88. The company has a market cap of $14.70 billion, a P/E ratio of -18.24 and a beta of 1.17. The stock’s 50-day simple moving average is $72.97 and its 200 day simple moving average is $59.13.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). The business had revenue of $120.70 million during the quarter, compared to analysts’ expectations of $107.71 million. The firm’s quarterly revenue was up 4318.0% on a year-over-year basis. During the same period last year, the company posted ($0.86) EPS. As a group, equities analysts predict that BridgeBio Pharma will post -3.67 earnings per share for the current fiscal year.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Lower near-term interest cost and extended maturity — the new notes carry 0.75% interest vs. the company’s 2.50% 2027 notes and push maturity to 2033, which should reduce cash interest expense and extend refinancing risk, improving balance-sheet flexibility. BridgeBio Prices Offering (GlobeNewswire)
• Positive Sentiment: Share repurchase tied to the deal reduces near-term float and may support the stock while also pushing the effective conversion price higher (helps limit immediate dilution). Management is using ~$82.5M cash to repurchase ~1.1M shares concurrently with the note pricing. QuiverQuant deal summary
• Positive Sentiment: Analyst/Wall Street tone is constructive — brokerages give a consensus “Moderate Buy” and recent price targets (median ≈ $86) remain above current levels, which supports investor confidence. Consensus Recommendation (AmericanBankingNews)
• Neutral Sentiment: Conversion terms limit near-term dilution — the initial conversion price is ~45% above the last trade, and conversions are restricted until certain conditions/periods (convertibility becomes more open closer to maturity), so dilution risk is muted in the short run. Finanznachrichten pricing details
• Negative Sentiment: Increased leverage and potential future dilution — the company is issuing incremental convertible debt (structurally junior to some obligations) and conversion or future redemptions could dilute equity holders over time; the offering is private (Rule 144A) and not registered. QuiverQuant private offering note
• Negative Sentiment: Insider selling and institutional adjustments noted in public data could weigh on sentiment — recent disclosures show sizable insider sales and some large institutional rebalances, which investors may view as a cautionary signal. QuiverQuant insider & institutional data

Insider Buying and Selling

In other news, CEO Neil Kumar sold 40,000 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $73.97, for a total value of $2,958,800.00. Following the transaction, the chief executive officer directly owned 735,686 shares of the company’s stock, valued at $54,418,693.42. This represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $66.65, for a total transaction of $666,500.00. Following the sale, the director directly owned 11,589 shares of the company’s stock, valued at $772,406.85. The trade was a 46.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 587,215 shares of company stock valued at $39,569,101. Insiders own 18.20% of the company’s stock.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors have recently made changes to their positions in the company. Corient Private Wealth LLC bought a new position in BridgeBio Pharma during the 2nd quarter worth $643,000. WINTON GROUP Ltd acquired a new stake in shares of BridgeBio Pharma during the 2nd quarter worth $3,856,000. Moss Adams Wealth Advisors LLC grew its holdings in shares of BridgeBio Pharma by 49.2% during the 2nd quarter. Moss Adams Wealth Advisors LLC now owns 24,172 shares of the company’s stock worth $1,044,000 after purchasing an additional 7,970 shares in the last quarter. Bosun Asset Management LLC increased its position in shares of BridgeBio Pharma by 119.7% in the second quarter. Bosun Asset Management LLC now owns 26,154 shares of the company’s stock worth $1,129,000 after purchasing an additional 14,250 shares during the period. Finally, Bryce Point Capital LLC acquired a new position in BridgeBio Pharma in the second quarter valued at about $598,000. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.